Abstract:Background: Erythropoiesis stimulating agents are exogenous erythropoietin medications that are used to stimulate the bone marrow red blood cells' production for the management of anemia of chronic kidney disease, some anticancer drugs, myelodysplastic syndrome, and others. Currently, there are different erythropoiesis stimulating agents accessible in the market. The objective of this narrative literature review is to summarize the role of some erythropoiesis stimulating agents in the treatment of anemia. Methods: The following method was used to prepare this narrative literature review. The comprehensive computerized search of literatures was carried out using PubMed, Cochrane library, Google scholar, and Science direct. Keywords such as recombinant human erythropoietin, epoetin, darbepoetin, continuous erythropoietin receptor agonist, pegzyrepoetin alfa, erythropoiesis stimulating agents in combination with anemia/anaemia were used. The pertinent original and review full articles which are written in the English language were included in this narrative review. Results: From the discussions of the literature, erythropoiesis stimulating agents that are produced by different biosimilar manufacturers have different clinical characteristics and stabilities as a result of their chemical modifications. The chemical modifications of erythropoiesis stimulating agents like glycosylation and polyethylene glycosylation determine the half-life, affinity to erythropoietin receptor, and immune response of the agents. Erythro-poiesis stimulating agents are categorized as short-acting and long-acting agents due to their chemical structures that influence the clinical efficacy and safety of the agents. Conclusions: The effectiveness of the agents is different in different patients depending on the individual characteristics and etiologies of anemia. The agents not only have the benefits but also, they have the risks for the patients. Hence, the risks and benefits of erythropoiesis stimulating agents must be given special consideration in the managements of anemia to get maximum efficacy for anemic patients. The treatment is dependent on hemoglobin levels of individual patients. The physician must follow the patients during and after therapy using erythropoiesis stimulating agents.

Challenges and recent advances in erythropoietin stability

Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

Physiology and pharmacology of erythropoietin

Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy

Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations

Erythropoietin: A Personal Alice in Wonderland Trip in the Shadow of the Giants

Research progress in erythropoietin mimetic peptides

Hypoxia Inducible Factor Stabilization As A Novel Strategy To Treat Anemia

New avenues of exploration for erythropoietin

Erythropoietin and Nonhematopoietic Effects

Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments

Progress of Erythropoietin for Patients with Renal Anemia

Recent Advancements in Erythrocytes, Platelets, and Albumin As Delivery Systems

Erythropoietin: a paradigm for the development of practice guidelines

Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli

[Erythropoietin: indications and measurement]

Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research

Improvement of in Vivo Efficacy of Recombinant Human Erythropoietin by Encapsulation in PEG&ndash;PLA Micelle

Role of Erythropoiesis Stimulating Agents in the Treatment of Anemia: a Literature Review

Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?"

A Review of Key Regulators of Steady-State and Ineffective Erythropoiesis